Drug Profile
Atorvastatin/aspirin/ramipril - Ferrer Internacional
Alternative Names: Aspirin/ramipril/atorvastatin; Atorvastatin/acetylsalicylic acid/ramipril; Atorvastatin/ASA/ramipril; Ramipril/atorvastatin/aspirin; TrinomiaLatest Information Update: 21 Sep 2022
Price :
$50
*
At a glance
- Originator Ferrer
- Developer Ferrer; HLS Therapeutics
- Class Antihyperlipidaemics; Antihypertensives; Cardiovascular therapies; Heart failure therapies; Heterocyclic bicyclo compounds; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cardiovascular disorders
- Phase II Hypertension
Most Recent Events
- 21 Sep 2022 Atorvastatin/aspirin/ramipril is still in preregistration for Cardiovascular disorders in Canada (PO) (Ferrer Internacional pipeline, September 2022)
- 27 Aug 2022 Efficacy data from a phase III SECURE trial in Cardiovascular disorders released by Ferrer Internacional
- 19 Feb 2020 Preregistration for Cardiovascular disorders in Canada (PO)